A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: ER+ Breast Cancer|HER2-negative Breast Cancer
Interventions: DRUG: Palbociclib 125Mg Tab|DRUG: Fulvestrant injection|DRUG: Tamoxifen|DRUG: Letrozole|DRUG: Exemestane|DRUG: Anastrozole
Sponsor: Royal Marsden NHS Foundation Trust
Collaborators: Pfizer|AstraZeneca|Institute of Cancer Research, United Kingdom|UNICANCER|Gustave Roussy, Cancer Campus, Grand Paris|Invitae Corporation